A Few Positives and Negatives For InMode Ltd. (INMD), Corcept Therapeutics Incorporated (CORT)

You should consider shares of InMode Ltd. (NASDAQ:INMD) and Corcept Therapeutics Incorporated (NASDAQ:CORT) if you are looking for a great stocks to invest in. Starting with the INMD shares, which traded at $43.99 at the close of the recent session, dropping -10.24%. On Tuesday, the company’s shares shed -$5.02 from its value which represented in intraday trading. INMD’s intraday high was $49.4499 while its lowest price touched $43.82. The stock’s 52-week high price is $58.76, which means the current price is at -25.14%. In terms of trading activity, the daily trading volume rose to 2193148 against 200-day average trading volume.

What are analyst forecasts for InMode Ltd. (NASDAQ:INMD)?

At a consensus rating of 5.00, INMD is trending as a streaking Strong Buy, as it has been the case a month ago when 4 analysts called it a Strong Buy. Two months ago, 4 analysts recommended, on average, that INMD stock is a Strong Buy. The Healthcare company’s shares’ overall bearish trend saw it close higher on Tuesday compared to its opening price of $46.47 on the day.

Forecasts for InMode Ltd. (NASDAQ:INMD) give the stock a fair value for the growth of 2.24% from its last price. The 12-month price forecast for the stock by analysts puts the stock’s mean price target at $45.00, which means the price per share could rise by nearly $1.01. The price range target is between a low of $44.00 and a high of $48.00. The stock would need to gain by about $8.35 to hit the estimated high or 0.3% from its 12-month low.

The consensus among 4 analysts is that it is a good time for one to Buy in the InMode Ltd. 3 analysts rate INMD as a Buy, with 0 of 4 analysts rate it as a Sell. 1 have valued the stock as Overweight and 0 have recommended that investors Hold.

InMode Ltd. (NASDAQ:INMD) Upgrades and Downgrades

In terms of rating changes, UBS on September 03, 2019, Initiated InMode Ltd. (INMD) at Buy. They believe the stock could reach $28 in the near term. Analysts at Robert W. Baird have assigned a Outperform rating for the stock in their research note on September 03, 2019 with an estimated price target of $27. Moreover, Canaccord Genuity analysts issued a rating of Buy for the stock on September 03, 2019, giving it a price target of $30 for the next 12 months. On September 03, 2019, the stock earned a Overweight rating due to an analyst call from Barclays.

Corcept Therapeutics Incorporated (NASDAQ:CORT) adds $0.5 on Tuesday

The CORT stock has risen 1.80% year-to-date and is currently trading at $13.60, which is -30.18% below its 52-week high. The company shares gained 3.82% on the day and have risen nearly 48.80% off a low hit. At current levels, Corcept Therapeutics Incorporated has a valuation of about $285.40M. As of 12/03/19, this stock has risen 5.67% during the week and closed at $13.10 in the previous session. However, recent Corcept Therapeutics Incorporated stock performance shows that CORT shares are -6.14% down over the last month, and 9.68% up for the last three months.

Earnings per share (EPS) estimates for the current quarter are $0.15, with the trailing 12-month share earnings at $0.71. The ratio is expected to be up by 28.30% for the current year 2019 and 27.30% for next year. Over the next 5-year period, earnings per share will be -41.40%. But will the CORT stock surprise in the current quarter results, where the $0.22 actual EPS reported on 9/29/2019 surprised by 10.00% or was higher by $0.02 from the estimated $0.2.

Sales Growth to climb 13.70% for the year

How well will Corcept Therapeutics Incorporated perform as a business over the current quarter, year and next 5-year period? Compared to the year-ago quarter, analysts forecast the company to bring in between $82.2M and $91.47M in current quarter sales. The consensus estimated for the current quarter is $87.85M from sales. Forecasts for this fiscal year are between $300.8M and $310.06M and the consensus estimate for sales is at $306.44M.

Who owns shares in Corcept Therapeutics Incorporated (CORT)?

Let’s briefly focus on the share ownership of the Corcept Therapeutics Incorporated (NASDAQ:CORT) stock, where we find that 79.82% of shares are held by institutions. Blackrock Inc. tops the list of institutional owners as it is holding 15.54 million shares or 13.60% of shares outstanding. Vanguard Group, Inc. (The) and Federated Investors, Inc. held 10.91 million and 9.24 million representing 9.54% and 8.09% respectively at the close of the last trading session. As of Sep 29, 2019, Ingalls & Snyder accounted for 8.71 million shares at over 123.15 million. This represented 7.62% of shares outstanding. Renaissance Technologies, LLC held 6.52 million shares at over 92.22 million representing 5.71% of shares outstanding.

CORT Insider Activity

Insider activity can also give a signal in terms of price direction. Looking at Corcept Therapeutics Incorporated (CORT), a total of 30000 shares have been sold by insiders over the last 6 months while 364218 shares were added in the same time span. On 12/12/2018, Chief Executive Officer by the name Belanoff Joseph K sold 217115.0 shares worth $4.1 million at the price of $19.01 per share. Filings also show that Belanoff Joseph K sold a total of 217115.0 shares on 12/12/2018 valued at $4.1 million. Since the last insider activity, the company’s share price has dropped -20.23%.